Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Here is a sample of the article.
Studies of other cardiovascular drugs include Amarin Corp. ’s plans to test whether its fish oil-derived drug, Vascepa, can prevent or treat Covid-19 infection and reduce the risk of cardiovascular problems in patients who sustained heart damage during their illness. It also wants to test whether the drug, first approved in 2012 to treat adults with very high levels of triglycerides, has antiviral effects.
Amarin says Vascepa may help prevent or treat inflammation caused when the SARS-CoV-2 virus attacks the endothelium, the layer of cells lining blood vessels and the inner walls of the heart chambers. Vascepa is a high-purity prescription form of eicosapentaenoic acid, or EPA, which has been shown to reduce a marker of inflammation, C-reactive protein.
“It quiets down inflammation,” said Deepak Bhatt, executive director of interventional cardiovascular programs at Brigham and Women’s Hospital and an investigator in a pilot study Amarin announced recently to test Vascepa as a treatment on hospitalized Covid-19 patients at the University of Toronto.
Amarin is planning studies elsewhere on health-care workers, people with underlying cardiovascular issues and other types of patients.
Statins, the cholesterol-lowering drugs taken by millions of Americans, have also shown promise as protective agents against serious Covid-19 complications.
Two large studies across several continents have suggested individuals with heart disease who were already taking statins were more likely to survive Covid-19 than those who weren’t taking the medicines, though the drugs’ potential effect hasn’t been directly tested yet.
In a 154-person analysis by researchers in Belgium, elderly patients taking statins were three times as likely to be free of Covid-19 symptoms. The observational study, published last month on a so-called preprint server, hasn’t been peer-reviewed.
Some trials are also studying the effect on Covid-19 patients of antiplatelet drugs, which prevent the formation of blood clots by keeping blood platelets from staying together, and of blood thinners, which are now routinely given at therapeutic doses to Covid-19 patients to prevent blood clots.
Full article link.
https://www.google.com/amp/s/www.wsj.com/amp/articles/heart-drugs-show-promise-with-covid-19-complications-11591102632
"Why do they give out this many to each of them now? Looks like a deal is already inked. Once shareholders approve, b/o news comes next, imo."
I hope this the case.
Would this info be found in Amarin investor relations?
Pulled from filing.
Items 5 through 9 and 11 of each of the cover pages to this Amendment No. 4 are incorporated herein reference. Set forth below is the aggregate number of ADS as well as ADS that may be acquired upon the conversion of the Series A Preference Shares (“Series A Preferred”), directly held by each of Baker Brothers Life Sciences, L.P. (“Life Sciences”) and 667, L.P. (“667”, and together with Life Sciences, the “Funds”), subject to the limitation on conversion described below. The Series A Preferred are convertible into ADS on a 10 for 1 basis and have no voting rights. The information set forth below is based on 358,906,887 ADS outstanding as of November 1, 2019, including 203,528 shares held as Ordinary Shares, as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on November 5, 2019. Each ADS represents 1 Ordinary Share of the Issuer. Such percentage figures are calculated in accordance with Rule 13d-3 under the Securities Exchange Act of 1934, as amended.
Name Number of ADS we own or have the right to acquire within 60 days Percent of Class Outstanding 667, L.P. 3,213,372 0.9%Baker Brothers Life Sciences, L.P. 31,283,313 8.7%Total 34,496,685 9.6%
The Series A Preferred are only convertible to the extent that the holders thereof together with their affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, no more than 4.99% of the outstanding Ordinary Shares or ADS of the Issuer after conversion (“Series A Beneficial Ownership Limitation”). As a result of this restriction, the number of shares that may be issued upon conversion of the Series A Preferred by the above holders may change depending upon changes in the outstanding shares. By written notice to the Issuer, the Funds may from time to time increase or decrease the Series A Beneficial Ownership Limitation applicable to that Fund to any other percentage not in excess of 19.9%. Any such increase will not be effective until the 61st day after such notice is delivered to the Issuer.
Thumbs up!
I have been a big follower of his investment when he was in Ariad. I think the problem here is the amount of shares he would need to be in control. It's probably wishful thinking and a main reason why it hasn't happened.
He is an activist investor. Recent deal was Mdco. Here is quick link of some of recent or past history.
https://endpts.com/hold-on-tight-a-disruptive-alex-denner-has-set-his-sights-on-creating-new-value-at-ironwood/
I would love to see Alex Denner here.
Just going by the 9/30/18 filing. But yes its all profit now.
They have an estimated average of $3.75 no point adding.
Solid find Raf. Thank you.
This article pretty much sums up what you said.
https://www.finnegan.com/en/insights/articles/litigating-for-appeal-practical-tips-for-patent-trial-counsel.html
Thanks as always!
This is a link for federal circuit year in review for 2017-18. Pretty detailed information.
Gibson Dunn › 2018/11 › Fe...PDF
2017/2018 Federal Circuit Year in Review - Gibson Dunn
Nice find indeed!
Anyone have any idea why institutional ownership is up almost 7%. I would think the opposite due to greater risk of appeal going south. Is this simply just averaging down or does smart money know something.
LOL so true!
Amarin up 23% in Frankfurt.
Above and beyond! Thank you!
Remember the Goldmans analyst $4 price target. They added 58% from the latest filing.
Baker Brothers Advisors LP discloses 9.60% ownership in AMRN / Amarin Corp. Plc
February 14, 2020 - Baker Brothers Advisors LP has filed an SC 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 34,620,057 shares of Amarin Corp. Plc (NASDAQ:AMRN). This represents 9.6 percent ownership of the company. In their previous filing dated February 13, 2019, Baker Brothers Advisors LP had reported owning 42,592,824 shares, indicating a decrease of -18.72 percent.
Looks like retail ran while institutions bought.
Price T Rowe Associates Inc /md/ reports 67.77% increase in ownership of AMRN / Amarin Corp. Plc
May 15, 2020 - Price T Rowe Associates Inc /md/ has filed a 13F-HR form disclosing ownership of 12,135,262 shares of Amarin Corp. Plc (NASDAQ:AMRN) with total holdings valued at $48,541,000 USD as of March 31, 2020. Price T Rowe Associates Inc /md/ had filed a previous 13F-HR on February 14, 2020 disclosing 7,233,061 shares of Amarin Corp. Plc at a value of $155,077,000 USD. This represents a change in shares of 67.77 percent and a change in value of -68.70 percent during the quarter.
Post in error.
February 13, 2019 - Healthcare Value Capital, LLC has filed a 13F-HR form disclosing ownership of 0 shares of Amarin Corp. Plc (NASDAQ:AMRN) with total holdings valued at $0 USD as of December 31, 2018. Healthcare Value Capital, LLC had filed a previous 13F-HR on November 13, 2018 disclosing 450,000 shares of Amarin Corp. Plc at a value of $7,322,000 USD. This represents a change in shares of -100.00 percent and a change in value of -100.00 percent during the quarter.
Healthcare Value Capital, LLC has a history of taking positions in derivatives of the underlying security (AMRN) in the form of stock options. The firm currently holds 200,000 call options valued at $800,000 USD .
Anxiously waiting for Baker filing also. I did see 6M add by another fund.
HealthCor Management, L.P. reports 389.23% increase in ownership of AMRN / Amarin Corp. Plc
May 15, 2020 - HealthCor Management, L.P. has filed a 13F-HR form disclosing ownership of 7,637,161 shares of Amarin Corp. Plc (NASDAQ:AMRN) with total holdings valued at $30,549,000 USD as of March 31, 2020. HealthCor Management, L.P. had filed a previous 13F-HR on February 14, 2020 disclosing 1,561,070 shares of Amarin Corp. Plc at a value of $33,469,000 USD. This represents a change in shares of 389.23 percent and a change in value of -8.72 percent during the quarter.
Thanks as always.??
You beef is with Du's ruling and the share price that followed.
You need to check your facts.
Would you have preferred they sell all 16M shares?
How does a stock get to $26 without institution?
Artisan Partners Limited Partnership reports 2.84% increase in ownership of AMRN / Amarin Corp. Plc
May 12, 2020 - Artisan Partners Limited Partnership has filed a 13F-HR form disclosing ownership of 16,511,551 shares of Amarin Corp. Plc (NASDAQ:AMRN) with total holdings valued at $66,046,000 USD as of March 31, 2020. Artisan Partners Limited Partnership had filed a previous 13F-HR on February 12, 2020 disclosing 16,055,421 shares of Amarin Corp. Plc at a value of $344,228,000 USD. This represents a change in shares of 2.84 percent and a change in value of -80.81 percent during the quarter.
Agreed! Nationality has nothing to do with anything. If she was European would she be labeled the same way. Probably not.
Appreciate the DD that many of you have done. ??
Saw this post awhile back. Is this valid.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=153411764
Can't respond to your pm. All good.??
Institutional ownership is actually higher. That number is behind by 45 days.
Currently it sits at 52.87%.
2020 Q1
$141M BOUGHT
$56M Sold